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The teratoma assay is the gold standard for documenting pluripotency of human stemcells. However, reports
of new human ESC and iPSC lines vary widely in both methods and analysis of teratoma data. We call for
consensus standards to be established to make this assay worthy of its ‘‘golden’’ status.In this journal, researchers have recently
participated in a lively discussion about
standards that could be used in charac-
terization of human pluripotent stem cells
(Daley et al., 2009; Ellis et al., 2009;
Maherali and Hochedlinger, 2008).
For mouse cells, the gold standard for
proving pluripotency is germline transmis-
sion (Bradley et al., 1984), which demon-
strates the ability to make all cell types,
including germ cells. For human cells, the
closest surrogate for the germline trans-
mission assay is the generation in immu-
nodeficient mice of human cell-derived
teratomas, solid tumors that contain a
mixture of differentiated tissues such a
neurons, heart muscle, and secretory
epithelia (Damjanov, 2005). Because of
the rich variety of mature histologically
distinct tissue types that develop, the
teratoma assay is currently regarded as
the most rigorous assay to prove pluripo-
tency of human stem cells.
Unfortunately, although the end point
of a germline transmission assay is simple
(a mouse derived from cultured cells), the
teratoma assay necessarily lacks this
level of absolute clarity. To determine
what methods and outcome measures
are used for teratoma analysis, we sys-
tematically screened the literature from
1998 to 2009 (Table 1). In spite of the
gold standard status of the teratoma
assay for determining pluripotency, we
found that there was little consistency in
either methods or reporting of results.
The protocols differed widely in key
parameters, such as preparation of cells,
site of injection, and number of cells
injected per animal. We found that the
majority of studies do not report key
factors, such as a systematic histopatho-412 Cell Stem Cell 6, May 7, 2010 ª2010 Elslogical evaluation or even the number of
mice transplanted.
The variation in reporting of teratoma
results brings up the question of this
assay’s value as a standard for proving
pluripotency of human stem cells. Given
the accelerating rate of derivation of new
human stem cell lines, we would like to
propose that the stem cell research com-
munity work toward improving the rigor of
assays used for defining cell pluripotency,
including the teratoma assay.
In many ways this situation is analo-
gous to the challenges faced by other
groups of scientists whenever novel or
little-used technologies capture the atten-
tion of researchers in prominent fields. For
example, the rapid adoption of microarray
technology in the late 1990s led to an
explosion of data in the literature, and
scientists became concerned about the
inconsistency of methods and reporting
of microarray data. The lack of standards
led to inaccurate reports and the broad
scientific community was justifiably sus-
picious of the methods (Loring, 2006). In
response to these concerns, users and
developers of microarray technology pro-
posed that researchers agree on a set
of standards for reporting of microarray
data (Brazma et al., 2001). These criteria,
called ‘‘Minimum Information About a
Microarray Experiment’’ (MIAME), have
transformed the reporting of microarray
data in the literature, simplifying the
review of manuscripts and building confi-
dence in the validity of the data.
In this Forum, we would like to initiate
a similar conversation about establishing
standards for the analysis of human plu-
ripotent stem cells. Focusing on the
most highly regarded assay for plu-evier Inc.ripotency, we propose that stem cell
researchers explore a systematic report-
ing system for teratoma experiments
and data. Such standards may aid plurip-
otent stem cell researchers to better eval-
uate and compare results across different
reprogramming strategies and differentia-
tion protocols and to contribute valuable
information about human development.
We surveyed more than 1200 original
research manuscripts that were pub-
lished from 1998 to 2009 in English lan-
guage journals, indexed in NCBI Medline,
and describing research on human
embryonic stem cells (hESCs). We also
identified 124 original research manu-
scripts that were published from 2007
to 2009 that report research on human
induced pluripotent stem cells (iPSCs).
For an initial survey of trends and main
findings, we analyzed in-depth 95 papers
describing the successful derivation of
639 novel hESC lines and 81 papers
describing the establishment of 777 novel
human iPSC lines (Table 1). Detailed
descriptions of reports and teratoma
results on the single manuscript level with
citations can be accessed in Table S1
available online.
To our surprise, we found that for more
than half of the 639 published hESC lines
(355 lines, 56%) and 64% of the published
iPSC lines (501 lines), no teratoma data
were included in the manuscripts that
reported the establishment of these cell
lines. These numbers indicate that the
gold standard for demonstration of pluri-
potency in human cells has been used
for only half of novel hESC and human
iPSC lines reported in the scientific litera-
ture. Although we are unable to analyze
the review process of manuscripts, our
Table 1. Summary of Our Systematic Literature Survey
Papers
Examined
Lines
Reported
Lines with
Teratoma Data
Avg. AIS of Journals
with Teratoma Data
Avg. AIS of Journals
without Teratoma Data Spearman Rank Correlation
hESC 95 639 44% 3.442 1.177 positive: 0.253 (p = 0.0134)
hiPSC 81 777 36% 7.339 8.165 weak positive: 0.084 (p = 0.4564)
Publications identified in a Pubmed/Medline search (see Table S1 for detailed screen and inclusion strategies) for novel hESC and hiPSC lines were
reviewed for inclusion of teratoma data. The Eigenfactor Article Influence Score (AIS) was retrieved for each article (see Table S1 for details and exam-
ples of relatively high and low AIS scores). The Spearman rank correlation, rho, was used assay for a correlation between the journal’s AIS and the
number of cell lines tested with the teratoma assay in a given study. Note: Papers reporting teratoma data of previously established cell lines
(follow-up studies) were not included in this analysis.
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for higher-impact journals are more likely
to require teratoma data in order to pass
peer review. Interestingly, when we ana-
lyzed the data, we discovered that our
impression was correct for hESCs, but
not for iPSCs; for novel hESCs, there was
significant positive correlation between
the impact (Eigenfactor Article Influence
Score) of a journal and inclusion of tera-
toma results, but for iPSC lines, although
there was a trend toward positive correla-
tion, there was no significant distinction
among journals (Table 1).
A second issue is the reporting of tera-
toma results. We found that even when
a teratoma assay is included, the method-
ology for inducing teratomas is often
poorly reported. The descriptions in the
methods sections varied so widely that
it was impossible to classify them into
groups. To illustrate the problem, we
describe several types of reporting that
are representative for the group of papers,
without identifying the specific papers.
The number of injected cells is often
reported with vague quantifications, for
example ‘‘clumps of 200–300 cells’’ with-
out mentioning how many of such clumps
were transplanted. Moreover, cell num-
bers for inductionof teratomasvarywidely;
even transplantations into the same site
are performed with cell numbers varying
more than three orders of magnitude
(e.g., 3000 to 5 million cells for testicular
injections). The time ‘‘in vivo’’ varies from
4 to 15 weeks, and the size of the resected
tumors ismentioned in very fewcases. Only
16 of the hESC and 3 of the iPSC papers
mention the passage number of the cells
used for teratoma experiments. Just 16 of
the hESC and only 10 of the iPSC papers
note the number of animals used for the
experiments. In six hESC reports and five
papers on iPSCs that report teratomas, no
single detail on how the teratomas were
induced and analyzed is given.In addition to the variability in informa-
tion reported for generating teratomas,
there is also a large inconsistency in
reporting of analysis of the tumors. The
teratomas are examined in most cases by
classic histological methods, via hema-
toxylin/eosin (H&E) stains, and usually
only isolated examples of tissue types
are provided, with no quantification or
basis for comparison across studies. In
general, a histopathologist is consulted
to identify tissue types within the tumor,
and to classify them as derivatives
from ectoderm, mesoderm, or endoderm.
Only a small fraction of the studies (17 of
75 hESC papers and 16 of 67 iPSC papers
that provided data on teratoma assays in
first reports of novel cell lines) included
immunohistochemical staining of tera-
tomas for differentiation markers. It is not
possible to quantify the types of tissues
reported because of the heterogeneity
of the reported results, but we have the
impression that the histological analysis
is generally subjective and dependent on
the experience of the pathologist.
We were also surprised to find that five
hESC lines were reported to fail to form
teratomas when injected into immunode-
ficient mice, and several lines formed
only small tumors consisting mainly of
fluid-filled cysts. Also, individual reports
indicated that it was difficult to obtain
well-differentiated teratomas from cer-
tain iPSC lines. This trend may be relevant
to our understanding of pluripotency,
because the ‘‘definitive’’ pluripotent stem
cell phenotype remains ill defined and it
has been reported by several indepen-
dent groups that even partially reprog-
rammed iPSC lines possess the ability to
form teratomas (Chan et al., 2009).
The clear conclusion from our review of
the literature is that accepted and prac-
ticed standards for both conducting and
reporting teratoma assays currently do
not exist. We would like to argue that ifCell Stem Cteratomas are to be regarded as the
gold standard for demonstrating pluripo-
tency, then the stem cell community
would benefit from development of con-
sensus standards for performing and
reporting teratoma results.
Another important reason for improv-
ing reporting of teratoma results is the
tremendous amount of information that
they can provide beyond their use as
proof of pluripotency. The cellular struc-
ture of teratomas has the potential to offer
insights into the development of human
embryonic tissues and differences among
cell lines. There are numerous questions
that could be addressed by following
consensus criteria for reporting teratoma
results. For example, does the site of
injection and number of cells affect the
types of tissues that develop and/or the
timing of their development? How mature
do tissues become in teratomas—do they
more resemble early stages of human
development or fully differentiated adult
tissues? Does the source of cell type for
reprogramming to iPSCs bias the differ-
entiation of the cells: for example, if carti-
lage precursors are reprogrammed, are
they better at making cartilage than cells
reprogrammed from dermal fibroblasts?
Can we use teratoma analysis to deter-
mine whether clinical transplants of deriv-
atives of particular stem cell lines are
more likely to form dangerous tumors
than others?
Of the two distinct issues regard-
ing teratomas, agreement about the
mechanics of teratoma generation (disso-
ciation methods, number of cells, site
of injection) may be easier to achieve
than coming to a consensus about stan-
dards for interpretation of teratoma
results (tumor descriptions, identification
of tissues). Because histological analysis
of embryonic tissues is a skill that had its
dominance in the 1950s and 1960s, very
few of the current generation of stemell 6, May 7, 2010 ª2010 Elsevier Inc. 413
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all in histology. As a result, the task of
assessing the tissue content of terato-
mas is usually outsourced to profes-
sional pathologists, and the stem cell
researchers who generated the teratomas
typically learn very little beyond a ‘‘check-
list’’ of isolated examples of derivatives of
the three germ layers: ectoderm, meso-
derm, and endoderm. This type of report-
ing adds little to our knowledge about the
variety of tissues and cell types that
develop in teratomas; there is not even
a standard basis for the identification of
a structure as a derivative of a particular
germline. As an anecdotal example, we
recently sought input from a local pathol-
ogist colleague during our analysis of
a group of teratomas generated from
human iPSCs. She noted the frequent
appearance of yolk sac cells in the
sections. The yolk sac is an extraembry-
onic endodermal tissue, and yolk sac
tumors, which are aggressively meta-
static, are most often found in testicular
tissue. Thus, it is reasonable for this cell
type to appear in stem cell-derived human
teratomas. But surprisingly, the literature
contains no reports of yolk sac tissue in
tumors generated for the purpose of
proving pluripotency of human stem cells.
With our preoccupation with identifying
tissues from the three germ layers, most
of us have lost sight of the fact that extra-
embryonic tissues play an essential role
during embryogenesis, and there is no
reason not to expect to find them in tera-
tomas. This observation raises an inter-
esting point that deserves further discus-
sion: in filling out the checklist of germ414 Cell Stem Cell 6, May 7, 2010 ª2010 Elslayers at the request of reviewers of
a publication, is it important whether the
histological identification of endodermal
derivatives in teratomas correctly distin-
guishes embryonic from extraembryonic
tissues?
We acknowledge that this Forum article
raises many questions and addresses
only a few. In particular, we have high-
lighted that reports of human pluripotent
lines are often devoid of teratoma data,
and when the assays are conducted,
they are performed, analyzed, and re-
ported inconsistently across the literature.
A recent methods publication authored
by the ISSCR standards committee (Ger-
tow et al., 2007) indicates that members
of the field can come together to begin
to establish consistency in methodology
and reporting. To extend this discus-
sion, we have compiled a list of criteria
(Table S2) that could potentially be incor-
porated into a standard teratoma report-
ing system. We would like to promote the
idea that having standards for reporting
methods and results of teratoma assays
will benefit the stem cell community, not
only by making the assay more reproduc-
ible, but also by providing deeper knowl-
edge about human development.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables and
can be found with this article online at doi:10.1016/
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